Contrasts in Glioblastoma—Venous Thromboembolism versus Bleeding Risk
Glioblastoma is among the tumor entities with an extreme thrombogenic potential and patients are at very high risk of developing a venous thromboembolism (VTE) over the course of the disease, with an incidence of up to 30% per year. Major efforts are currently being made to understand and gain novel...
Main Authors: | Viktoria Muster, Thomas Gary |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/6/1414 |
Similar Items
-
Incidence, Therapy, and Bleeding Risk—Cancer- Associated Thrombosis in Patients with Glioblastoma
by: Viktoria Muster, et al.
Published: (2020-05-01) -
Platelet count and risk of major bleeding in venous thromboembolism
by: Håkon S. Johnsen, et al.
Published: (2021-05-01) -
Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
by: Ramón Lecumberri, et al.
Published: (2021-07-01) -
Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol
by: Faizan Khan, et al.
Published: (2019-10-01) -
Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
by: Géraldine Poénou, et al.
Published: (2023-08-01)